×

RNS Number : 4687C

Dev Clever Holdings PLC

21 June 2021

 

21 June 2021

 

Dev Clever Holdings plc

 

("Dev Clever" or the "Company")

 

Tactical Partnership and Contract Agreement with Aldebaron DMCC

 

-US$50 million minimum guaranteed revenues over next 4 years-

 

Dev Clever (LSE: DEV), a leading developer of online and immersive career guidance and development platforms, is pleased to announce that it has secured a breakthrough tactical partnership with Aldebaron DMCC ("Aldebaron").  Aldebaron is a Dubai based organisation focused on the distribution, delivery and implementation of consumer facing technology and next generation impactful digital solutions into emerging markets across the world. 

 

The tactical partnership is an immediate major endorsement of the Company's announcement earlier today regarding the acquisition and activation of multiple Career Challenge ("CC") initiatives first scheduled for the UK and India. 

 

Background

The Company announced on 3 February 2021 that it had secured a material licensing agreement for its core EdTech services, with an unnamed client ("the Client").  This agreement related to the Client's forthcoming new "social media" proposition and today's agreement with Aldebaron is a seamless extension of that original arrangement.  During the past several months various aspects of the Dev Clever proposition have been successfully tested in closed Beta with the Client and today's Aldebaron agreement becomes the central conviction "go to market education initiative" for the Client.   The Company remains under strict NDA with the Client and Aldebaron (together the "Parties") until general release of the Client's exciting proposition. 

 

Platform integration

There will be a full platform integration to deliver the best possible support and frictionless experience for students, brands, employers and educational institutions to understand, connect, engage and transact.  This will include other activities such as enabling students to communicate, interact and curate with their peers, for example by taking part in live Q&A from participating companies and in social and community activities both in the digital and physical world. 

 

Dev Clever, the Client and Aldebaron anticipate that this bespoke end-to-end solution can provide a transformational and positively disruptive tool for work experience and recruitment to manage the longer-term career for many millions of young individuals whilst concurrently providing a highly tailored and inclusive solution for many brands, employers and educational institutions across the world.

 

Partnership terms

The tactical partnership will enable the Company to commit to a vastly accelerated global rollout plan across Asian territories, starting in India in partnership with NISA and then extending across Indonesia, Thailand, Singapore, Malaysia, Philippines and into the Middle East and Africa over the next three years.

 

To facilitate this accelerated rollout, Aldebaron in conjunction with the Client, have undertaken to provide Dev Clever with the following minimum US$ revenue guarantees for the financial years ending 31 October:

 

· FY21: 5 million

· FY22: 10 million

· FY23: 15 million

· FY24: 20 million

 

The Partners are expected to enter into complementary long-term subscription and transaction revenue and profit share arrangements at the signing of definitive documentation and prior to the full roll-out of the services.  Moreover, there is a rolling option to extend the Aldebaron partnership for an additional two years with a minimum additional commitment of US $20 million per annum in favour of Dev Clever.  The Parties will work closely together and expect to achieve considerable incremental economic and other benefits when it comes to attracting brands, employers and educational institutions from becoming active endorsers and participants of the proposed initiatives as described above.   

 

Aldebaron Equity Purchase Right

In consideration for the tactical partnership between Aldebaron and the Company and the proposed minimum guaranteed revenue streams, Dev Clever will grant to Aldebaron :

 

· Option to acquire seven million Dev Clever shares at a nominal value during the period commencing on the date of signing definitive documentation for the tactical partnership and ending on the expiry of six months thereafter; and

· Warrant to subscribe for 60 million Dev Clever shares at a price of 60 pence per share, exercisable for a period of three years from the date of grant.  This warrant once issued would be assignable under certain conditions by Aldebaron.

 

Chris Jeffries, Chief Executive Officer of Dev Clever, commented:

"This partnership is transformational for the Company and for the innovative end-to-end proposition we can offer students in terms of careers guidance.  At the same time brands, employers and educational institutions can through hyper personalisation start to activate and target young individuals and students much more effectively.  We have made really substantive progress over the past eighteen months and whilst there is a lot of incremental work to be done, we are genuinely confident that today is the starting point of delivering a game-changer solution for our stakeholders in the relatively near-term future."

 

Ben Manners, Director of Aldebaron DMCC, commented:

"We are pleased to be partnering with Dev Clever in order to help accelerate their international rollout plans into the Asia and MENA regions.  The vibrancy and desire to progress in life from young individuals and students in emerging markets is undiminished.  Aldebaron strongly believes that collaboration and connecting the right touch points early in life will create much better and long-lasting connections between youth and relevant education on the one hand and seamlessly into early and longer-term career roles and development on the other hand.  We believe strongly that the smart integration of Dev Clever's innovative and proven solutions with our partner proposition has the clear potential to benefit the future livelihoods of tens of millions across the world and at the same time deliver much better outcomes for brands and employers.  That is very clearly worth investing into and that is absolutely what we intend to do'.   

 

This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

 

-ends-

 

 

 

 

For further information please contact:

Dev Clever Holdings plc Christopher Jeffries Chief Executive Officer and Executive Chairman   Nicholas Ydlibi Chief Financial Officer	+44 (0) 1827 930 408
Novum Securities Limited – Financial Adviser and Broker David Coffman / Colin Rowbury	+44 (0) 20 7399 9400
Aldebaron DMCC Ben Manners – via Buchanan Communications	+44 (0) 20 7466 5105
Buchanan Communications Richard Oldworth / Chris Lane	+44 (0) 20 7466 5105

 

 

Notes to Editors

 

Dev Clever Holdings plc, together with its wholly owned subsidiary DevClever Limited, is a software and technology group based in Tamworth, United Kingdom, specialising in the use of lightweight integrations of cloud-based VR and gamification technologies to deliver rich customer engagement experiences across both the education and commercial sectors. In January 2019, Dev Clever listed on the Standard List of the London Stock Exchange. The Group's core focus is the development and commercialisation of its core platforms – Educate (its primary focus) and Agency Services (its secondary focus).

Educate Division:

 

Through Educate, Dev Clever aims to reduce the global skills shortage by delivering an enhanced careers guidance service via its online platform, Launchyourcareer.com, and virtual reality software (Victar VR). The business has established a global partnership with Lenovo to roll its service worldwide, with offerings already on the market in the UK, US and Canada. Dev Clever is also focused on the Indian market and has partnered with its National Independent Schools Alliance (NISA) and content provider Veative to provide a comprehensive service offering within Indian budget private schools. Through this, the business is developing and intends to launch a direct-to-consumer offering in India.

Agency Services:

 

The Company's Agency Services division provides customers from the retail, brand and hospitality sectors with bespoke application and customisation of the Group's proprietary cloud-based products in order to increase consumer engagement, transactional efficiencies and enhance customer experience within their venues.

 

For further information, please visit www.devcleverholdingsplc.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

AGRDKKBPKBKBCAB

Close

×

Neville Registrars is delighted to welcome TECC Capital Plc as the newest addition to its list of client companies.

TECC Capital is a SPAC listed on the Access Segment of the AQSE Growth Market focussed on investing in businesses which are developing and/or supporting the application of technology in innovative sectors.

Further information can be found on the Company's website: https://tecccapital.com/

Close

×

Neville Registrars is delighted to welcome Pharma C Investments Plc as the newest addition to its list of client companies.

Pharma C Investments is an Investment Vehicle set up to identify and pursue opportunities and acquisitions in companies to specifically take advantage of the burgeoning commercial and dynamic regulatory environment surrounding legal medicinal cannabis.

Further information can be found on the Company's website: http://www.pharmacinvestments.com/

Close

×

RNS Number : 8008Z

Netcall PLC

26 May 2021

 

 

26 May 2021

RNS REACH

 

NETCALL PLC

("Netcall", the "Company" or the "Group")

 

Netcall launches Tenant Hub on the Liberty platform

New integrated automation and communications offering for the housing sector

 

Netcall plc (AIM: NET), a leading provider of intelligent automation and customer engagement software, is today launching a new Liberty platform solution, Tenant Hub, tailored to address the specific needs of the housing sector.

 

Like other industries, the housing sector is implementing digital transformation initiatives to streamline operations and improve increasingly complex customer interactions. The importance of these initiatives is further amplified by an expected surge in housing demand as a result of the lock-down placing the housing sector under increasing pressure1.

 

Powered by Netcall's Liberty platform, Tenant Hub is a housing specific suite of solutions centred on Liberty Create low-code capabilities, with self-service and integration to Liberty's omnichannel contact centre solutions.   The result for tenants is improved online access to vital services, including rent statements and repair services, as well as more choice when it comes to engaging – including via Twitter and Facebook Messenger.

 

Customers of Tenant Hub will also have access to the Netcall AppShare Community, where housing associations collaboratively can share new and build upon existing applications to continuously deliver improved efficiencies and greater tenant experiences.

 

 

Henrik Bang, CEO of Netcall, commented : "This is our third Hub joining Patient Hub and Citizen Hub on the Liberty platform. We continue to build new innovative solutions to meet the needs of specific industry verticals and help organisations across all sectors in their pursuit of a 'digital first' strategy. The Group currently has approximately 120 local authority and housing association customers, and today's announcement represents a new significant opportunity to expand our services to both existing and new customers."

1 https://www.theguardian.com/society/2020/nov/14/waiting-list-for-council-homes-in-england-will-double-to-2-million

 

For further enquiries, please contact:

 

Netcall plc	Tel. +44 (0) 330 333 6100
Henrik Bang, CEO
Michael Jackson, Chairman
James Ormondroyd, Group Finance Director
Canaccord Genuity Limited  (Nominated Adviser and Broker)	Tel. +44 (0) 20 7523 8000
Simon Bridges / Andrew Potts
Alma PR	Tel. +44 (0) 20 3405 0205
Caroline Forde / Hilary Buchanan / Robyn Fisher

 

About Netcall

Netcall's Liberty software platform with Intelligent Automation and Customer Engagement solutions helps organisations transform their businesses faster and more efficiently, empowering them to create a leaner, more customer-centric organisation. 

 

Netcall's customers span enterprise, healthcare and government sectors. These include two-thirds of the NHS Acute Health Trusts and leading corporates such as Legal and General, Lloyds Banking Group, ITV and Nationwide Building Society.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAUVAKRAAUVUAR

Close

×

RNS Number : 8051Z

Pharma C Investments PLC

26 May 2021

 

26 May 2021

Pharma C Investments Plc

("Pharma C" or the "Company")

 

ADMISSION TO TRADING ON THE AQSE GROWTH MARKET, CLOSING OF THE £1 MILLION FUNDRAISING & FIRST DAY OF DEALINGS

 

Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with particular focus on ancillary businesses, is pleased to announce that admission of the Company's ordinary shares to trading on the AQSE Growth Market ("Admission") will take place and dealings will commence at 8.00 am GMT today, Wednesday 26th May 2021, under the symbol "PCIL"   (ISIN: GB00BJDPYD55).

Highlights

· Successful £1 million fundraising at 0.7p per share

· Pharma C will focus on investing in ancillary businesses in the cannabis sector which are scalable and defensible with IP, technology and data assets

· Pharma C has a strong, female-led team with expertise in the entrepreneurial and medicinal cannabis sector, meaning the Board and management team have a superior ability to identify breakout companies based on an in-depth understanding of cannabis industry dynamics

· Pharma C has a world-class advisory board with strong experience across the medical and medicinal cannabis sectors, providing the Company with valuable insights and guidance when looking at prospective investments

· The Company has unique access to medicinal cannabis ancillary businesses in the early-stage, pre-IPO deal flow from a global network of medical cannabis experts

· Pharma C will seek to take board positions where possible to enhance growth and support the creation of positive impact businesses while delivering top quartile returns to investors

· Pharma C will primarily focus on companies across the UK, Europe and Israel, where

o  The European market is set to be the largest cannabis market in the world with over 750 million people and a total healthcare spend of €2.3 trillion

o  Cannabis has been used for medical purposes in Israel since 1996, with broader prescription programmes adopted in 2011 and around 80,000 patients in Israel are directly prescribed cannabis, up from 20,000 patients three years ago

· The funds raised will be used to:

o  Pursue the Company's immediate objective of developing a portfolio of investments

o  Meet general working capital requirements, undertake due diligence on potential target investments and to make investments in accordance with the investment strategy

o  Provide working capital to cover the Company's ongoing annual operating costs

Chana Greenberg, CEO of Pharma C Investments, commented, "This listing marks a significant milestone for Pharma C Investments and will provide the market with the opportunity to be part of an investment vehicle led by strong entrepreneurs and focused on the profitable and robust ancillary market in the medicinal cannabis sector. 

"The opportunities around medicinal cannabis across Europe and further afield are huge and we are excited to be able to utilise first mover advantage in the growing market. Our unique investment strategy will provide our shareholders with a diverse portfolio of high-quality businesses whilst ensuring these companies receive the support and guidance they need to thrive."

 

– Ends –

 

For additional information please contact:

 

Pharma C	Tel: +44 7897 834 092
	Chana Greenberg, CEO	[email protected]
Beaumont Cornish Limited (Corporate Adviser)	Tel: 0207 628 3396
	James Biddle
	Roland Cornish
Blytheweigh (Financial PR/IR-London)	Tel: +44 207 138 3204
	Tim Blythe	[email protected]
	Megan Ray	[email protected]
Pello Capital (Broker)
	Callum Hill	[email protected]

 

About Pharma C Investments

Pharma C Investments is an investment vehicle targeting the legal medicinal cannabis industry globally. The Company is seeking to identify breakout companies within the legal markets with a particular focus on the UK, EU and Israel and will provide capital, strategic insights and operational support. Pharma C is run by cannabis entrepreneurs who understand the unique challenges of the legal cannabis industry and thus can provide invaluable support and expertise for growing companies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXPPUAUAUPGPPA

Close

×

Neville Registrars is delighted to welcome Dianomi plc as the newest addition to its list of client companies.

Dianomi is a leading provider of native digital advertising services to premium clients in the Financial Services and Business sectors.

Further information can be found on the Company's website: https://www.dianomi.com/

Close

×

RNS Number : 0613Z

Vulcan Industries PLC

19 May 2021

 

 

Vulcan Industries plc

("Vulcan" or the "Company")

 

Contract Win

 

Vulcan Industries (AQSE: VULC) is pleased to announce new contract wins for M+G Olympic.

 

M+G Olympic, the wholly owned subsidiary of Vulcan, has recently won over £500,000 of new contracts for the installation of its new range of swimming pools. These installations range from 50m Olympic size municipal swimming pools to smaller private leisure pools.

 

Increased demand for leisure facilities during Covid-19 lockdowns has seen a significant increase in demand for bespoke swimming pool installations and M+G Olympic is perfectly positioned as one of the leading EXC2 certified designers, manufacturers and installers of custom built architectural metalwork specifically for swimming pools.

 

In addition, M+G Olympic has been short-listed for the prestigious "CE East Midlands building project and innovation of the year award" for its work on the landmark restoration and transformation of the Derby Silk Mill into the Museum of Making.

 

The Museum is the first of its kind to use the Integrated Project Insurance ("IPI"), the UK Governments new construction model of procurement. The Museum of Making is expected to attract around 140,000 visitors per year. M+G Olympic worked closely with both Lyon Architects and main construction contractor Speller Metcalf to create contemporary steel staircases, balustrades and walkways, which are sympathetic to the historical features of the Silk Mill whilst meeting the stringent safety requirements of a public attraction. The 16.4m project was supported with funding from the National Lottery Heritage Fund, Arts Council of England.

 

Ian Tordoff, Chairman, commented; "We are delighted by the progress the sales and estimating team are making at M&G. I understand the Silk Mill project team were particularly happy with the work from our drawing office too. As the country recovers we are making changes across the group to ensure Vulcan is fit and ready to meet the growing demand from its customers."

 

For further information, visit: https://vulcanplc.com  

Contacts

Vulcan Industries plc	Via Vox Markets
Ian Tordoff, Chairman
John Maxwell, CEO
First Sentinel Corporate Finance Ltd (AQSE Corporate Adviser)	+44 7876 888 011
Brian Stockbridge
Gabrielle Cordeiro
Vox Markets (Media and Investor Relations)	[email protected]
Kat Perez	+44 7881 622 830
Paul Cornelius	+ 44 7866 384 707

 

 

About Vulcan

Vulcan seeks to acquire and consolidate traditional but historically profitable engineering, manufacturing and industrial SMEs for value and to enhance this value in part through group synergies, but primarily by unlocking growth which is not being achieved as a standalone private company. Learn more at Vulcan Industries on Vox Markets .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXUWSKRAVUVAAR

Close

×

RNS Number : 3748W

Genedrive PLC

23 April 2021

 

REACH

genedrive plc

("genedrive" or the "Company")

 

Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces the publication of a large independent multi-centre study evaluating the real-world performance of the Genedrive®HCV -ID Kit in low and middle income countries. The study yielded sensitivity specifications of 96.2 – 100%, and specificity specifications of 98.7 – 99.5%, depending on the site or viral load. The results confirm that the Genedrive®HCV -ID Kit is effective as intended in the diagnosis of HCV infection in resource limited settings. Importantly, the authors highlight a test fail rate of only 1.6%, showing that the Genedrive® system performs to this high standard even though the system operators in the study had no previous experience in molecular testing.   

 

The study, published in the journal Diagnostics (Lamoury et al, 2021, 11, 746) was conducted in Georgia and Cameroon, and enrolled 426 participants, which had very different demographic backgrounds. The participants in the Georgia trial were almost all intravenous drug users. Intravenous drug users are a key patient population for HCV infection. The Genedrive sensitivity and specificity results were obtained by comparison to testing with the Abbott RealTime HCV Assay. The publication can be accessed on line at https://www.mdpi.com/2075-4418/11/5/746 . The study was conducted by The Foundation for Innovative New Diagnostics (FIND), with grant funding provided by Unitaid.

 

The study's findings also corroborate other key performance capabilities of the Genedrive®HCV -ID Kit, including the ability of the kit to identify all major HCV genotypes, the utility of requiring small volumes of plasma, and the lack of hazardous chemicals in the Genedrive kits construction, allowing for normal disposal processes versus competitor products that require heat incineration.  

 

David Budd, Chief Executive Officer of genedrive plc, said:  "This study is the first large scale, independent multi centre evaluation from low and middle income markets using the Genedrive HCV test. While the performance results are as expected and excellent, it is equally gratifying to see these achieved with operators with no previous experience in molecular testing.  Moving testing from highly complex and automated central hospital settings towards more simple decentralised settings is a balance of technological complexity, cost, performance, and usability, which is not always an easy balance to achieve.  This study is an excellent demonstration   of real world performance and the ability of Genedrive to contribute to fighting HCV in resource limited settings."  

 

The Genedrive® HCV -ID Kit allows for decentralised molecular testing of Hepatitis C (HCV) by PCR, providing results within 90 minutes direct from a small plasma sample (30 µl). This allows for testing to be done outside of a large hospital facility and indeed while a patient may be waiting for a result. The assay is performed on the Genedrive® platform, the only truly portable molecular diagnostics system designed for diagnosing HCV at the point of need.  

 

For further details please contact:

 

genedrive plc	+44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	+44 (0)20 7418 8900
James Steel / Victoria Erskine
finnCap (Joint Broker)	+44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 or [email protected]
Paul McManus / Anna Dunphy	+44 (0)7980 541 893 / +44 (0)7876 741 001

 

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRASEAFUEEFSEEL

Close

×

RNS Number : 1992W

YouGov PLC

21 April 2021

 

21 April 2021

 

YouGov plc

 

("YouGov" or the "Company")

 

YouGov Safe: Redefining the possibilities of online customer data

for consumers and clients

 

· Fully opt-in, GDPR & CCPA compliant data marketplace, which places the power over personal data in the hands of the consumer

· Takes customer profiling to the next level by seeing the reality of what consumers stream, search for and purchase online across devices and platforms

· Combines observed online behaviours and transactions with attitudinal insights from YouGov's flagship YouGov Profiles tool to provide three-dimensional consumer intelligence data

 

YouGov, the international research and data analytics group, has launched YouGov Safe – a fully opt-in, GDPR & CCPA compliant, ethical cross-device tracker and data marketplace. YouGov Safe will provide media owners, brands and agencies with a transparent view of consumers' verified online behaviours and transactions and reward consumers for choosing to share their data.

 

YouGov Safe is the latest innovative data enhancement to the YouGov platform – providing next-level customer profiling, by observing what the public is actually consuming and purchasing online, adding further depth to reported behaviour data the industry currently uses. This, combined with attitudinal insights from YouGov Profiles, provides truly connected 3D consumer intelligence data.

 

In keeping with YouGov's ethos of providing value for individuals, YouGov Safe places the power over personal data directly in the hands of the consumer. YouGov Safe enables members to securely store data that companies, platforms and institutions hold on them, and then share it with selected third parties anonymously or on a case-by-case approval basis.  It forms a data marketplace for the user, empowering them to choose exactly what information is shared and with whom. Members receive points that count towards a cash payment every time they allow a new company to have an interaction with their data.

 

The first available output from the product is data from major international streaming platforms and services. Additionally, YouGov Safe can already provide online retail data and users' browsing history. In the near future, this will expand to include banking, gaming and health data.
 

Because of the ethical and fully-permissioned way it has been designed, YouGov Safe means brands, media owners and agencies can get a more complete view of consumers in a number of ways:

 

· Target based on browser history, banking data, actual shopping habits, 'micro-influencer' status and more

· Conduct unrivalled seed marketing at a granular level

· Get visibility on the marketing-to-purchase funnel, understanding marketing ROI based on verified purchases

· Target and re-contact individual members with 1:1 panel access

· Strategise and innovate with competitor research on a product level

· Access global cross-platform streaming viewership and shopping data to compare and contrast habits

· Find optimal sponsorship deals based on purchase journeys, such as matching brands with influencers, studios with products

· Access social media user behavioural data to target fans of particular pages, followers of celebrities/brands based on engagements

· Create audience segments of verified subscribers, survey watchers/listeners of specific shows to compare and contrast viewership across platforms and markets

 

Hamish Brocklebank, Head of YouGov Safe: "For too long consumers, brands, agencies and media owners have been let down by online behavioural and transaction data. YouGov Safe changes the game for everyone. For consumers, it is the opportunity to have the power over their personal data – deciding what to share, doing it in a secure way and getting value for it. For clients, YouGov Safe takes customer profiling to another level – understanding their audience's full journey across devices – whether it is streaming, gaming, shopping, or other online activity – and connecting it to YouGov's rich attitudinal data. YouGov Safe redefines the possibilities of connected customer data for both consumers and clients."

 

Enquiries:

YouGov plc

YouGov plc Stephan Shakespeare / Alex McIntosh / Hannah Jethwani	020 7012 6000
FTI Consulting Charles Palmer / Elena Kalinskaya	020 3727 1000
Numis Securities (NOMAD and Joint Broker) Nick Westlake / Hugo Rubinstein / Matt Lewis	020 7260 1000
Berenberg (Joint Broker) Mark Whitmore / Alix Mecklenburg-Solodkoff	020 3207 7800

 

 

About YouGov

 

YouGov is an international research and data analytics group.

Our mission is to supply a continuous stream of accurate data into what the world thinks, so that organisations can better serve the communities that sustain them. 

Each day, our highly engaged proprietary global panel of over 15 million registered members provides us with thousands of data points on consumer opinions, attitudes and behaviour. We combine this continuous stream of data with our research expertise to provide insights that enable intelligent decision-making and informed conversations.

With operations in the UK, North America, Mainland Europe, the Nordics, the Middle East and Asia Pacific, YouGov has one of the world's largest research networks.

YouGov
Best panel
Best data
Best tools

For further information visit yougov.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAUAUURAAUSUAR

Close

×

RNS Number : 9444V

Crimson Tide PLC

20 April 2021

 

20 April 2021

Crimson Tide agrees three year SaaS contract with

 World Federation of Haemophilia

 

Crimson Tide ("Crimson Tide" or "the Company" (AIM:TIDE), the provider of mpro5 is pleased to announce that it has signed a three year agreement with the World Federation of Haemophilia (WFH). This follows the successful completion of the pilot phase announced by the Company on January 26, 2021.

The agreement will initially enable up to 100 clinicians globally to use mpro5 to scan pharmaceuticals, verifying their expiry and authenticity, and allowing the WFH to gain real-time insights into product usage. The mpro5 platform will be integrated into WFH's DPUMS system enabling real-time data captured from mpro5 to be available to all users around the world, replacing the ineffective existing paper-based data input..

mpro5 provides barcode scanning, data analysis, and cloud-based services via Microsoft Azure, renowned for its reliability, scalability and security.  This enables real-time information, automated alerting, and integration capabilities with the existing systems of the WFH, driving a more efficient, transparent, and safer supply chain. mpro5 has been used in healthcare for many years in the verification and patient management for the National Coagulation Centre (NCC) in Ireland. It has also been used in verification of counterfeit drugs for the World Health Organisation in Africa and Asia.

The WFH is based in Montreal, Canada and its vision is that of Treatment for All and that one day, all people with a bleeding disorder will enjoy a more certain future filled with promise, no matter where they live. The mission of the WFH is to improve and sustain care for people with inherited bleeding disorders around the world. In order to achieve this, the organisation actively pursues long-term relationships with individuals and organizations who share the values inherent in their comprehensive development model.

Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are delighted that we have been able to demonstrate the unique qualities of mpro5 to the WFH in such a short space of time. This supports our belief that there are significant opportunities to use our solutions throughout the wider healthcare sector and to help deliver improved patient outcomes. We look forward to working with the WFH and supporting them in their outstanding work."

For further information:

 

Crimson Tide plc

Barrie Whipp / Luke Jeffrey      +441892 542 444

 

finnCap (Nominated Adviser and Broker)

Corporate Finance: Julian Blunt / James Thompson     +44 20 7220 0500

Corporate Broking: Andrew Burdis    +44 20 7220 0500

 

Alma PR (Financial PR)

Josh Royston  +44 7780 901979

 

For further information on Crimson Tide plc, see the website at: www.crimsontide.co.uk/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTGPUMCCUPGGAB

Close